Breaking News

Financial Report: Lilly

July 24, 2013

Revenues up 6% in the quarter


2Q Revenues: $5.9 billion (+6%)

2Q Earnings: $1.2 billion (+31%)

YTD Revenues: $11.5 billion (+3%)

YTD Earnings: $2.8 billion (+42%)

Comments: Cymbalta sales increased 22% to $1.5 billion in the quarter. Cialis sales increased 13% to $529.4 million. Revenue in the U.S. increased 13% to $3.4 billion driven by increased prices, primarily for Cymbalta. Revenue outside the U.S. decreased 2% to $2.5 billion, impacted by foreign exchange rates, primarily the Japanese yen, and the loss of market exclusivity for Zyprexa (-25% to $283.2 million). Higher revenue and ongoing cost containment drove earnings growth.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks